Dari rioH
- Health
th Corp.
- rp.
Per erso sonal nalized H ed Heal ealth h Management anagement
NASD SDAQ: D DRI RIO
Dari rioH oHealth th Corp. orp. Per erso sonal nalized H ed - - PowerPoint PPT Presentation
Dari rioH oHealth th Corp. orp. Per erso sonal nalized H ed Heal ealth h Management anagement NASD SDAQ: D DRI RIO Forw orward rd Look ooking S g Sta tate tements This presentation of DarioHealth Corp. (the Company) and
NASD SDAQ: D DRI RIO
statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future
statements within the meaning of the Act.
perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. Factors that could cause or contribute to such differences include, but are not limited to our compliance with regulatory requirements, the impact of current and any future competition, our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise, our ability to manufacture, market and generate sales of our Dario™ diabetes management solution, as well as other factors and risks discussed in the Company’s filings (including the results of the company’s commercial and regulatory plans for Dario™) with the U.S. Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
have been prepared by our management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to our future performance. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles.
NASDAQ: DRIO 2
NASDAQ: DRIO 3
Employees
New York
Headquartered
Founded
Countries with users
Regulatory bodies approvals
Countries fully reimbursed
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company with personalized, mobile health solutions. We believe in empowering people with chronic conditions, with more control and independence to manage their daily challenges and changes. Harnessing the power big data, we’re able to give each person unparalleled, real-time insights and the guidance they need to navigate their unique journey.
NASDAQ: DRIO 4
2017 Revenue
Qua uarter terly R Rev evenue enue
$67 $175 $273 $308 $568 $669 $728 $838 $1,007 $1,210 $1,375
$0 $200 $400 $600 $800 $1,000 $1,200 $1,400
Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017
(in thousands)
NASDAQ: DRIO 5
People with diabetes (2017)
People with diabetes projected by 2045
German any
Since Q3 2017
Netherlan ands
Since Q3 2016 Insurance Coverage
USA SA
Since Q2 2016 Partial Coverage
Ita taly ly
Since Q1 2016 Insurance Coverage
Can anad ada a
Since Q4 2015 Insurance Coverage
Austr tralia lia
Since Q3 2015 Insurance Coverage
UK UK
Since Q1 2015 Insurance Coverage
Population with Diabetes by Country
Dario currently has access to
Pre-diabetes projected by 2035*
* Pred Prediabet etes diagno nosis and nd t trea reatment ment: : A rev review ew, , by by Nihdi di Bans nsal, , 15 15 Ma Mar 2015 2015
theories
technology
NASDAQ: DRIO 6
7
Total annua nnual a avera erage e med edica cal co costs
$11, 11,000 000 - $13, 13,700 700 A person with diabetes with complications can cost as much as $20,700 annually
* American Diabetes Association (ADA), The Cost of Diabetes, Last reviewed Oct 2013, http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html, (Accessed Nov 2017).
Total annua nnual a avera erage e diabet etes es-speci ecific co c costs
$7, 7,900 900 Studies tudies ha have s e sho hown tha n that t Dario io’s 1% % reductio eduction n in H in HbA bA1c y c yields ields s subs ubsta tantia ntial l sav avings gs $80 80 - $100 100 per per pa patient tient per per m month. nth. $35. 35.8 8 billio billion n of po f potentia tential l saving ings to to the the U.S. hea healthca lthcare e system tem.
8
Device & App
Data and performance driven
– Lower coast – Clinical outcomes
Targeted coaching approach
Dario Engage Platform provides full coverage, scalable healthcare solutions that are easily customized to integrate with any clinical programs covering all facets
Type1, Type2, gestational diabetes, and prediabetes.
9
Personalized health guidance 100% data capture, real-time data sync to secure cloud storage Personalized platform, mobile application, coaching, digital guiding, community, support Clinical program integration, automated processes, and reporting
BT Sync Dedicated Offline
10
NASDAQ: DRIO 11
Continue to Add Members Upsell Products & Services Enter the Employer Market & Health Partners Expand Into Additional Countries Support Other Disease States Monetize The Data Over the Long-Term
Long-Term Near-Term 2017 2018 2019 and beyond Current offering Dario Engage services Other digital services Market Reach
Enter the Employer Market & Health Partners
Dario Engage Services (2018-2019)
Expand Into Additional Countries
Support Other Disease States
Prediabetes (84.1M), Pregnancy, Weight loss, Sport and more)
Other Digital Services (2019 and beyond)
Monetize on Data and AI
Add Members
Current offering (2018)
Upsell Products & Services
NASDAQ: DRIO 12
An experienced management team with vast software, medical device and technology experience guided by a world class Board Of Directors and Scientific Advisory Board.
Zvi Ben-David
CFO
device companies. Among his previous roles, he served as Corporate VP & CFO of Given Imaging, where he was a part of the founding team and also helped lead the start-up to a $65 million annual revenue commercial enterprise as well as its successful initial and follow-on public offerings.
Dror Bacher
COO
in product development at both mobile and semi-conductor companies. Previously, he held numerous executive positions, including a leadership role at Amdocs, managing enterprise development programs.
Adiel Levin
Global Senior Director, Sales and Commercialization
experience in the telecommunications, financial services and health sectors, in both B2B and B2C. He has managed global sales teams, channel partners and distribution networks in the EMEA and APAC regions for telecom, healthcare and financial services industries.
Erez Raphael
CEO & Chairman
industries including mobile, life science, medical device, health IT, mHealth and digital health solutions.
Yinon Amir
Head of Software
technologies, solution architecture and design, as well as large scale projects management and customer delivery management. Previously, he held senior management positions at Amdocs, a global leader in telecommunications customer experience and billing solutions.
Olivier Jarry
Strategic Advisor
centricity for three decades on five continents. He has had several executive roles in life sciences multinationals such as leading the global Diabetes Care division of Bayer.
Shmuel Herschberg
Director, Marketing and User Engagement
possesses a unique blend of technical understanding coupled with strategic thinking and customer psychology. Previously he held a senior position at an interactive, direct-to-consumer marketing company where he was responsible for creating successful revenue streams.
Janice Baker
RDN, CDE
Janice Baker has been providing diet counseling and medical nutrition therapy since 1982, specializing in weight management, diabetes education, and cardiac risk reduction. A graduate of California Polytechnic State University, San Luis Obispo, Good Samaritan Hospital Internship, and National University, Janice also holds a Master’s Degree in Business Administration as well as a Bachelor of Science Degree in Dietetics and Food Administration. She is a Certified Nutrition Support Dietitian and has been a Certified Diabetes Educator since 1992. In 2012, Janice became Board Certified in Advanced Diabetes Management.
NASDAQ: DRIO 13
NASDAQ: DRIO 14
NASDAQ: DRIO 15
– 62% users under recurring plans
Consistent Revenue Growth
NASDAQ: DRIO 16
$67 $175 $273 $308 $568 $669 $728 $838 $1,007 $1,210 $1,375
$0 $200 $400 $600 $800 $1,000 $1,200 $1,400
Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017
(in thousands)
Revenue by Region - Q1:Q3 2017 Subscriptions Vs. One Time - 2017
One timers-US Subscribers-US Reimbursement and Insurance Coverage
US Other
NASDAQ: DRIO 17
Long-Term Near-Term 2017 2018 2019 and beyond Current offering Dario engage services Other digital services Market Reach
Device and consumables
$25 per user/month
Coaching platform to employers and payers
$25 per user/month
premium services at
$5 per user/month
NASDAQ: DRIO 18
Current offering Dario Engage services Other digital services Target year total Y/Y growth rate Market penetration
0.50%
0.75%
1.00%
1.25%
1.50%
1.75%
2.00%
2.25%
2.50%
2.75%
3.00%
3.25%
3.50%
in $ M
NASDAQ: DRIO 19
NASDAQ: DRIO 20
v YE2017
Shares Outstanding
14,074,238
Warrants Outstanding
3,685,056
ESOP
2,554,299
Percentage of Insider Holdings
45.8%
Debt
Management invested so far more then $3M into the company.
NASDAQ: DRIO 21
Investor Relations
Westwicke Partners Tel: 1-443-213-0500 Dario@Westwicke.com
R&D Center
8 Hatokhen Street North Industrial Park Caesarea 389000 Israel
Headquarters
142 W 57th Street 11th Floor New York, NY 10019 USA partnershipgroup@mydario.com www.dariohealth.com
NASDAQ: DRIO 22